Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data
Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data
批准号:
10229386
负责人:
Paul Englund Drawz
金额:
$69.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-17 至 2023-06-30
关键词:
Acute Renal Failure with Renal Papillary NecrosisAddressAdultAmerican Heart AssociationBenefits and RisksBlood PressureBradycardiaCardiovascular DiseasesCardiovascular systemChronic DiseaseClinicClinical TrialsCodeCreatinineDataData SourcesElectronic Health RecordEnd stage renal failureEventFutureGoalsGoldGuidelinesHeart failureHypernatremiaHypertensionHypotensionICD-9ImpairmentIncidenceIndividualInpatientsIntervention TrialKidneyKnowledgeLinkLongitudinal prospective studyMeasurementMeasuresOutcomeOutpatientsParticipantPatientsPhasePhysiciansPragmatic clinical trialProtocols documentationProviderRecommendationRenal functionReportingResearchRiskRisk FactorsSiteStrokeTechniquesTranslationsVisitadjudicateadjudicationadverse event riskadverse outcomebaseblood pressure interventionclinical practicedesignfollow-uphyperkalemiamortalitypragmatic trialscreening
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Hypertension is prevalent in 68.5 million U.S. adults and is one of the leading chronic disease risk factors in the
world. The Systolic Blood Pressure Intervention Trial (SPRINT) evaluated the effect of intensive (<120 mmHg)
and standard (<140 mmHg) BP targets on cardiovascular events and all-cause mortality. Intensive BP lowering
was associated with a 25% reduction in cardiovascular events and a 27% reduction in all-cause mortality. BP
measurement in SPRINT followed guideline adherent protocols. Unfortunately, BP measurement in routine
clinical practice is often not adherent to American Heart Association recommendations; inappropriate
technique is associated with an overestimation of BP by approximately 5 to 15 mmHg. Therefore, the achieved
BP in routine clinical practice during the treat to target phase of SPRINT is unknown. An additional limitation of
SPRINT is that acute kidney injury (AKI) was only assessed in the inpatient setting and adjudication was based
on billing codes and discharge summaries, not the gold standard for assessing AKI – creatinine values.
Fortunately, SPRINT was one of the first large trials performed in the era of electronic health records (EHRs).
The timing of the SPRINT trial provides a unique opportunity to link SPRINT data to EHR data to perform
analyses that would be otherwise infeasible within either data source alone. The goals of the proposed study
are to a) inform implementation of the SPRINT results by comparing contemporaneous BP in the routine clinic
setting to those measured at SPRINT study visits, b) provide creatinine values to assess the effect of intensive
and standard BP targets on rates of AKI and other renal outcomes during the trial and in long-term, post-trial
follow-up, and c) inform the design of future pragmatic clinical trials by reporting on the concordance between
EHR based and formal SPRINT based assessment of renal and cardiovascular outcomes. For the proposed
study, SPRINT and EHR data (BP and creatinine values and ICD-9/10 codes) from a number of the larger
SPRINT sites will be linked. The specific aims are to evaluate 1) the concordance between BP measured in the
general clinic setting to BP measured using guideline recommended technique at SPRINT research visits; 2)
the effect of intensive versus standard BP targets on renal and cardiovascular outcomes using SPRINT and
EHR based creatinine values; and 3) the concordance between EHR based and formal SPRINT based
assessment of renal and cardiovascular outcomes to inform the design of future pragmatic clinical trials. Our
results will support physicians and clinic managers in their efforts to implement appropriate BP measurement
protocols and will inform implementation of the SPRINT results. Finally, this study will be the first to link clinical
trial data with EHR data on a large scale and will serve as an example for how these types of data can be
merged to leverage the strengths of both data sources.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Home Blood Pressure Outcomes Evaluation Study (HOMESTEAD)
-
批准号:10364199
-
项目类别:
-
资助金额:$49.43万
-
财政年份:2022
-
负责人:Paul Englund Drawz
-
依托单位:
Home Blood Pressure Outcomes Evaluation Study (HOMESTEAD)
-
批准号:10619516
-
项目类别:
-
资助金额:$47.19万
-
财政年份:2022
-
负责人:Paul Englund Drawz
-
依托单位:
Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data
-
批准号:9398771
-
项目类别:
-
资助金额:$93.45万
-
财政年份:2017
-
负责人:Paul Englund Drawz
-
依托单位:
Effect of Standard vs Intense Hypertension Management on Nighttime Blood Pressure
-
批准号:8768575
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2014
-
负责人:Paul Englund Drawz
-
依托单位:
Effect of Standard vs Intense Hypertension Management on Nighttime Blood Pressure
-
批准号:8898067
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2014
-
负责人:Paul Englund Drawz
-
依托单位:
Epidemiology and pathophysiology of elevated nighttime blood pressure in CKD
-
批准号:8065537
-
项目类别:
-
资助金额:$16.65万
-
财政年份:2010
-
负责人:Paul Englund Drawz
-
依托单位:
Epidemiology and pathophysiology of elevated nighttime blood pressure in CKD
-
批准号:8514589
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2010
-
负责人:Paul Englund Drawz
-
依托单位:
Epidemiology and pathophysiology of elevated nighttime blood pressure in CKD
-
批准号:8299093
-
项目类别:
-
资助金额:$16.7万
-
财政年份:2010
-
负责人:Paul Englund Drawz
-
依托单位:
Epidemiology and pathophysiology of elevated nighttime blood pressure in CKD
-
批准号:7875585
-
项目类别:
-
资助金额:$15.64万
-
财政年份:2010
-
负责人:Paul Englund Drawz
-
依托单位:
Epidemiology and pathophysiology of elevated nighttime blood pressure in CKD
-
批准号:8686829
-
项目类别:
-
资助金额:$16.55万
-
财政年份:2010
-
负责人:Paul Englund Drawz
-
依托单位:
海外基金